IQVIA Holdings, Inc. (IQV) revealed a planned leadership change in its financial department on Tuesday. The company announced that Michael Fedock, who currently holds the position of Senior Vice President of Financial Planning & Analysis, will step into the role of Executive Vice President and Chief Financial Officer, with the transition set to take effect on February 28, 2026.

Fedock is slated to take over from Ron Bruehlman, who will be retiring from his position as CFO after a notable tenure. To ensure a smooth transition and maintain continuity, Bruehlman will continue to serve in an advisory capacity to Chief Executive Officer Ari Bousbib.

Bruehlman's journey with IQVIA began in 2011 when he joined IMS Health as CFO. His contributions were pivotal in the company's Initial Public Offering in 2014 and the subsequent merger between Quintiles and IMS Health in 2016. In 2020, Bruehlman came out of retirement to lend his support to IQVIA during a crucial period.

Since joining IQVIA in 2016, Fedock has occupied various senior financial positions within the organization. His roles have included serving as CFO of IQVIA's Research & Development Solutions business unit and as CFO of IQVIA Laboratories.

Before his tenure at IQVIA, Fedock held several leadership positions at ICON plc and other healthcare organizations, accumulating experience across both pharmaceutical and hospital environments.